作者
Maria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, Peter Kufer, Max S Topp, Hermann Einsele, Richard Noppeney, Georg Hess, Stefan Kallert, Andreas Mackensen, Kathrin Rupertus, Lothar Kanz, Martin Libicher, Dirk Nagorsen, Gerhard Zugmaier, Matthias Klinger, Andreas Wolf, Brigitte Dorsch, Beate D Quednau, Margit Schmidt, Jürgen Scheele, Patrick A Baeuerle, Eugen Leo, Ralf C Bargou
发表日期
2016/4/1
期刊
Journal of Clinical Oncology
卷号
34
期号
10
页码范围
1104-1111
出版商
American Society of Clinical Oncology
简介
Purpose
Blinatumomab is a CD19/CD3 BiTE (bispecific T-cell engager) antibody construct for the treatment of Philadelphia chromosome–negative acute B-lymphoblastic leukemia. We evaluated blinatumomab in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).
Patients and Methods
This 3 + 3 design, phase I dose-escalation study determined adverse events and the maximum tolerated dose (MTD) of continuous intravenous infusion blinatumomab in patients with relapsed/refractory NHL. Blinatumomab was administered over 4 or 8 weeks at seven different dose levels (0.5 to 90 μg/m2/day). End points were incidence of adverse events, pharmacokinetics, pharmacodynamics, and overall response rate.
Results
Between 2004 and 2011, 76 heavily pretreated patients with relapsed/refractory NHL, who included 14 with diffuse large B-cell lymphoma, were enrolled; 42 received treatment in the formal dose …
学术搜索中的文章
ME Goebeler, S Knop, A Viardot, P Kufer, MS Topp… - Journal of Clinical Oncology, 2016